NASDAQ:OCUP
Ocuphire Pharma, Inc. Stock News
$1.69
-0.0500 (-2.88%)
At Close: May 17, 2024
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Friday, 09'th Jul 2021
FARMINGTON HILLS, Mich., July 09, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely o
OCUP Stock Price Increases Over 30%: Why It Happened
09:55am, Wednesday, 30'th Jun 2021
The stock price of Ocuphire Pharma Inc (NASDAQ: OCUP) increased by over 30% during intraday trading this morning. This is why it happened.
Ocuphire Pharma Stock Surges After Nyxol Combo Treatment Meets Study Endpoints In Presbyopic Patients
08:00am, Wednesday, 30'th Jun 2021
Ocuphire Pharma Inc (NASDAQ: OCUP) announced data from the VEGA-1 Phase 2 trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects. Pr
Ocuphire's VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints
07:15am, Wednesday, 30'th Jun 2021
Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol ® plus low-dose pilocarpine (LDP) gaining ≥ 15 letters (3 lines) in near vision
Processa Pharmaceuticals In-Licenses Ocuphire's Anticancer Agent
01:55pm, Thursday, 17'th Jun 2021
Processa Pharmaceuticals Inc (NASDAQ: PCSA) has entered into a licensing agreement with Ocuphire Pharma Inc (NASDAQ: OCUP) to in-license RX-3117. RX-3117 is an oral anticancer agent with an impro
Ocuphire Announces Addition to the Russell Microcap® Index
07:30am, Friday, 11'th Jun 2021
FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of t
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
04:10pm, Tuesday, 08'th Jun 2021
Capital Raise Expected to Extend Runway Through Late 2022 and Allow Additional Milestones for a Potential NDA Filing for Nyxol in Reversal of Mydriasis Capital Raise Expected to Extend Runway Through
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
09:04am, Friday, 04'th Jun 2021
FARMINGTON HILLS, Mich., June 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi
Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
01:35am, Thursday, 13'th May 2021
Ocuphire's Low Market Cap Masks Significant Pipeline Potential
Ocuphire Pharma Starts Mid-Stage APX3330 Study In Diabetic Retinopathy Patients
10:43am, Thursday, 08'th Apr 2021
Ocuphire Pharma Inc (NASDAQ: OCUP) has screened the first patient in Phase 2 ZETA-1 trial evaluating APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic reti
Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
08:31am, Thursday, 08'th Apr 2021
APX3330 has the Potential to be a Novel Oral Treatment Option with Dual Mechanism of Anti-VEGF and Anti-Inflammatory for Diabetic Retinopathy
Ocuphire Pharma Stock Price: $25 Target By Alliance Global Partners
08:14am, Monday, 05'th Apr 2021
The shares of Ocuphire Pharma Inc (NASDAQ: OCUP) have increased by over 10% pre-market. This is why it happened.
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:10pm, Thursday, 01'st Apr 2021
FARMINGTON HILLS, Mich., April 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely
OCUP Stock Price Increases Over 90% Pre-Market: Why It Happened
06:53am, Monday, 15'th Mar 2021
The stock price of Ocuphire Pharma, Inc. (Nasdaq: OCUP) is trading at over 90% pre-market as of 6:47 AM ET today. This is why it happened.